Dublin, July 05, 2019 (GLOBE NEWSWIRE) -- The "Capmatinib" report has been added to ResearchAndMarkets.com's offering.
Capmatinib (Incyte/Novartis) is an orally bioavailable inhibitor of the proto-oncogene c-MET, also called hepatocyte growth factor receptor (HGFR).
C-MET is a receptor tyrosine kinase, and abnormal activation in cancer can trigger tumor growth, angiogenesis, and metastasis. As a result, patients with aberrant c-MET activity typically have poor prognosis, aggressive disease, and shortened survival. Capmatinib selectively binds to c-MET, thereby disrupting c-MET signaling pathways. This can induce cell death in tumor cells with high c-MET amplification.
Key Topics Covered
List of Figures
Figure 1: Gilotrif sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017-26
Figure 2: Imfinzi for non-small cell lung cancer - SWOT analysis
Figure 3: Tagrisso sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017-26
Figure 4: The authors drug assessment summary for Tecentriq in non-small cell lung cancer
List of Tables
Table 1: Capmatinib drug profile
Table 2: Capmatinib pivotal in non-small cell lung cancer
Table 3: Capmatinib early-phase data in non-small cell lung cancer
Table 4: Gilotrif sales for NSCLC across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 5: Capmatinib patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017-26
For more information about this report visit https://www.researchandmarkets.com/r/f71xpu
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Oncology Drugs